Kinstellar advises shareholders of Quinta-Analytica on acquisition by Genesis Private Equity Fund
Kinstellar has successfully advised shareholders of the Czech company QUINTA-ANALYTICA, an established provider of R&D and regulatory services for the pharmaceutical, biotechnology and generic drug industries, on the sale of their 75 per cent share in QUINTA-ANALYTICA to Genesis Private Equity Fund III (GPEF III). The transaction represents a first investment for GPEF III, which […]